NervGen Pharma (NGEN)
NASDAQ:NGEN
Want to see NGEN full AI Analyst Report?
NGEN Analyst Ratings
Strong Buy
5 Buy
0 Hold
0 Sell
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months
NGEN Stock 12 Month Forecast
Average Price Target
$11.90
▲(192.38% Upside)
| Highest Price Target$18.00 | Average Price Target$11.90 | Lowest Price Target$5.50 |
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.
Detailed List of Analyst Forecasts
Detailed List of Analyst Forecasts
H.C. Wainwright
$18
Buy
342.26%
Upside
Reiterated
04/28/26
Stifel Nicolaus
$6
Buy
47.42%
Upside
Reiterated
04/28/26
Lucid Capital
$18
Buy
342.26%
Upside
Initiated
04/15/26
Research Capital
$5.5
Buy
35.14%
Upside
Reiterated
04/10/26
Is NervGenPharma still undervalued?Uddin said the pivotal study is expected to enroll about 150 patients at roughly 60 sites across the United States and Canada, with startup activity already underway and trial initiation still expected around mid-2026. He said enrollment could be completed in the second half of 2027, with topline data in the first half of 2028 and a potential NDA filing in the second half of 2028.
Maxim Group
$10→$12
Buy
194.84%
Upside
Assigned
04/09/26
Paradigm
$3.67→$7.11
Buy
74.78%
Upside
Reiterated
06/17/25
Raymond James
$2.55→$4.4
Buy
8.11%
Upside
Reiterated
06/11/25
Analyst Type
Any
Ranks
Any
Analyst Rating
Any
Upside/ Downside
Any
Action
Any
H.C. Wainwright
$18
Buy
342.26%
Upside
Reiterated
04/28/26
Stifel Nicolaus
$6
Buy
47.42%
Upside
Reiterated
04/28/26
Lucid Capital
$18
Buy
342.26%
Upside
Initiated
04/15/26
Research Capital
$5.5
Buy
35.14%
Upside
Reiterated
04/10/26
Is NervGenPharma still undervalued?Uddin said the pivotal study is expected to enroll about 150 patients at roughly 60 sites across the United States and Canada, with startup activity already underway and trial initiation still expected around mid-2026. He said enrollment could be completed in the second half of 2027, with topline data in the first half of 2028 and a potential NDA filing in the second half of 2028.
Maxim Group
$10→$12
Buy
194.84%
Upside
Assigned
04/09/26
Paradigm
$3.67→$7.11
Buy
74.78%
Upside
Reiterated
06/17/25
Raymond James
$2.55→$4.4
Buy
8.11%
Upside
Reiterated
06/11/25
Best Analysts Covering NervGen Pharma
3 Months
xxx
Success Rate
2/3 ratings generated profit
Average Return
+11.27%
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 3 Months would result in 66.67% of your transactions generating a profit, with an average return of +11.27% per trade.
1 Year
Success Rate
3/3 ratings generated profit
Average Return
+102.87%
Copying Michael W. Freeman's trades and holding each position for 1 Year would result in 100.00% of your transactions generating a profit, with an average return of +102.87% per trade.
2 Years
xxx
Success Rate
3/3 ratings generated profit
Average Return
+70.17%
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 2 Years would result in 100.00% of your transactions generating a profit, with an average return of +70.17% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.
NGEN Analyst Recommendation Trends
Rating
Dec 25
Jan 26
Feb 26
Mar 26
Apr 26
Strong Buy
1
1
0
1
6
Buy
0
0
0
1
5
Hold
0
0
0
0
0
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
1
1
0
2
11
Each month's total comprises the sum of three months' worth of ratings.
NGEN Financial Forecast
NGEN Stock Forecast FAQ
What is NGEN’s average 12-month price target, according to analysts?
Based on analyst ratings, NervGen Pharma’s 12-month average price target is 11.90.
What is NGEN’s upside potential, based on the analysts’ average price target?
NervGen Pharma has 192.38% upside potential, based on the analysts’ average price target.
Can I see which stocks the top-ranking analysts are rating?
Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
How can I follow the stock ratings of top Wall Street analysts?
Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
Is NGEN a Buy, Sell or Hold?
NervGen Pharma has a consensus rating of Strong Buy which is based on 5 buy ratings, 0 hold ratings and 0 sell ratings.
What is NervGen Pharma’s price target?
The average price target for NervGen Pharma is 11.90. This is based on 5 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $18.00 ,the lowest forecast is $5.50. The average price target represents 192.38% Increase from the current price of $4.07.
The highest analyst price target is $18.00 ,the lowest forecast is $5.50. The average price target represents 192.38% Increase from the current price of $4.07.
What do analysts say about NervGen Pharma?
NervGen Pharma’s analyst rating consensus is a Strong Buy. This is based on the ratings of 5 Wall Streets Analysts.
How can I buy shares of NGEN?
Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.